Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.0K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.0K
Drugs that Destabilize Microtubules01:10

Drugs that Destabilize Microtubules

3.2K
Microtubules are dynamic structures and can be regulated by microtubule targeting agents (MTAs). Microtubule destabilizing drugs are a class of MTAs that destabilize and prevent microtubules' polymerization. Both natural and synthetic chemicals can be found under this class of drugs. Vincristine and vinblastine, two vinca alkaloids, and colchicine were among the first to be discovered. These drugs can affect cells in various ways, either by inducing a change in cell morphology, preventing...
3.2K
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase01:11

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

81
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
81
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

3.0K
Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
3.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A novel amide-quinoline salt-based mitochondrial-targeted fluorescent probe for detecting pH in cells and water samples.

Spectrochimica acta. Part A, Molecular and biomolecular spectroscopy·2026
Same author

A dansyl-quinolinium-based ratiometric fluorescent probe for detecting HSO<sub>3</sub><sup>-</sup>/SO<sub>3</sub><sup>2-</sup> in living cells.

Analytica chimica acta·2025
Same author

A near-infrared fluorescent probe based FRET for ratiometric sensing of H<sub>2</sub>O<sub>2</sub> and viscosity in live cells.

Talanta·2024
Same author

A highly sensitive ratiometric fluorescent probe for detecting HSO<sub>3</sub><sup>-</sup>/SO<sub>3</sub><sup>2-</sup> and viscosity change based on FRET/TICT mechanism.

Analytica chimica acta·2024
Same author

A ratiometric fluorescent probe based on the FRET platform for the detection of sulfur dioxide derivatives and viscosity.

Analytica chimica acta·2024
Same author

A FRET-based ratiometric fluorescent probe for sensing bisulfite/sulfite and viscosity and its applications in food, water samples and test strips.

Food chemistry·2023
Same journal

Erratum to PGK1-coupled HSP90 stabilizes GSK3β expression to regulate the stemness of breast cancer stem cells.

Cancer biology & medicine·2026
Same journal

Less is more: patients with cervical cancer benefit from de-escalated chemotherapy plus immuno-targeted therapies.

Cancer biology & medicine·2026
Same journal

Unveiling molecular incomplete response (mIR) <i>via</i> ultra-deep NGS: a novel concept contrasting pathologic complete response (pCR) in occult lymph node micrometastases of non-small cell lung cancer.

Cancer biology & medicine·2026
Same journal

Gut microbiome: an emerging player and therapeutic target in cancer.

Cancer biology & medicine·2026
Same journal

Thermal ablation <i>versus</i> loop electrosurgical excision procedure and cold knife conization for cervical intraepithelial neoplasia: efficacy and HPV clearance in a 5-year cohort of Chinese women.

Cancer biology & medicine·2026
Same journal

Toward the precision use of Chinese PARP inhibitors in ovarian cancer: clinical progress, resistance mechanisms, and future perspectives.

Cancer biology & medicine·2026
See all related articles

Related Experiment Video

Updated: May 4, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

5.9K

Why bortezomib cannot go with 'green'?

Li Jia1, Feng-Ting Liu2

  • 1Center for Hemato-Oncology, Barts Cancer Institute, St Bartholomew's Hospital, Barts Health NHS Trust, Queen Mary University of London, London E1 4NS, UK.

Cancer Biology & Medicine
|December 19, 2013
PubMed
Summary
This summary is machine-generated.

Dietary flavonoids and vitamin C can interfere with the cancer drug bortezomib. Patients undergoing bortezomib treatment should avoid these compounds found in fruits, vegetables, and green tea to ensure treatment effectiveness.

Keywords:
Bortezomibflavonoidsmyelomapolyphenols

More Related Videos

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.1K
Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux
09:18

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Published on: September 17, 2019

4.4K

Related Experiment Videos

Last Updated: May 4, 2026

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors
07:57

Malachite Green Assay for the Discovery of Heat-Shock Protein 90 Inhibitors

Published on: January 20, 2023

5.9K
Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice
11:25

Busulfan as a Myelosuppressive Agent for Generating Stable High-level Bone Marrow Chimerism in Mice

Published on: April 1, 2015

13.1K
Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux
09:18

Measuring Diurnal Rhythms in Autophagic and Proteasomal Flux

Published on: September 17, 2019

4.4K

Area of Science:

  • Oncology
  • Nutritional Science
  • Pharmacology

Background:

  • Dietary antioxidants like flavonoids and vitamin C are widely consumed for their potential health benefits, including cancer prevention.
  • Bortezomib is a proteasome inhibitor used to treat multiple myeloma, but it is less effective against blood-based leukemic cells.
  • Concurrent use of supplements and dietary components with chemotherapy is common among cancer patients.

Purpose of the Study:

  • To investigate the potential antagonistic interactions between dietary flavonoids/vitamin C and the chemotherapeutic agent bortezomib.
  • To elucidate the mechanisms by which dietary compounds may neutralize bortezomib's efficacy.
  • To provide evidence-based recommendations for patients undergoing bortezomib treatment.

Main Methods:

  • Literature review summarizing existing research on flavonoid and vitamin C interactions with bortezomib.
  • Analysis of chemical interactions between flavonoids, vitamin C, and bortezomib.
  • Review of pharmacokinetic and pharmacodynamic data related to bortezomib and dietary components.

Main Results:

  • Certain flavonoids and vitamin C have been shown to have an antagonistic effect on bortezomib.
  • These dietary compounds can neutralize bortezomib through direct chemical interactions in the bloodstream.
  • The interaction may explain why bortezomib is less effective in eliminating leukemic cells.

Conclusions:

  • Dietary flavonoids and vitamin C should be avoided by patients receiving bortezomib chemotherapy.
  • Avoiding these dietary components is crucial to prevent interference with bortezomib's anti-cancer activity.
  • Further research is warranted to fully understand the clinical implications of these interactions.